about
News on the genetics, epidemiology, medical care and translational research of SchwannomasPAK kinase regulates Rac GTPase and is a potential target in human schwannomasLongitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.Spinal neurofibromatosis without café-au-lait macules in two families with null mutations of the NF1 gene.Hereditary demyelinating neuropathies: from gene to disease.A functional association between merlin and HEI10, a cell cycle regulator.Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies.Achieving consensus for clinical trials: the REiNS International Collaboration.Conclusions and future directions for the REiNS International Collaboration.Hereditary motor neuropathies and motor neuron diseases: which is which.FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patientsMerlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathwaysNeurofibromatosis type 1 with involvement of the enteric nerves.Expression of decorin mRNA in the nervous system of rat.Magic but treatable? Tumours due to loss of merlin.Schwannomas and their pathogenesis.Management of sialorrhoea in motor neuron disease: a survey of current UK practice.Cellular prion protein (PrP(C)) in the development of Merlin-deficient tumours.DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.Activation of multiple growth factor signalling pathways is frequent in meningiomas.Artesunate induces necrotic cell death in schwannoma cells.Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.Cellular contaminants of adeno-associated virus vector stocks can enhance transduction.The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state.Reduced apoptosis rates in human schwannomas.Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.Tetracycline-inducible transgene expression mediated by a single AAV vector.Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins.The epidemiology of motor neurone disease in two counties in the southwest of England.PO76GROWTH FACTOR SIGNALLING PATHWAYS IN MENINGIOMAS IS COMMON AND PARTLY DEPENDS ON SUBTYPE ALLOWING FOR STRATIFICATION.P06.02ACTIVATION OF MULTIPLE GROWTH FACTOR SIGNALLING PATHWAYS IS FREQUENT IN MENINGIOMAS.
P50
Q28283074-1446AF6E-A760-4777-AD30-9638E800AFE9Q30490902-C4A00D60-9EE3-4F97-96FE-FE9DC46A985AQ33561323-FE22AE9E-2D51-49E5-92E8-BF43C16C3BD5Q33809716-3229FCBC-D187-405B-B905-154E6C7177D8Q34044901-31BFE815-4531-4455-9692-FADB8551E0D8Q34252129-E99C0FF3-8DBE-4184-AFEA-51E33A749C99Q34501518-B82F3A32-4886-4824-A999-28EC9048D85BQ34915893-C10A7FE3-8C6D-47C2-8E5B-8F43C6A054E9Q35046436-4B71057D-F848-4A28-BD5A-C4A079FD3A29Q35046441-5AC93A99-BE9B-4FB4-A512-EF6683D24B21Q35113116-F28D148B-5262-4418-9CE3-98AA42B868BCQ35445374-CD6EE977-0704-4BAE-9811-BD0DCCDA9E88Q35670477-09186F79-71FB-48E6-9501-D34B8D69D6B4Q36226694-70197583-C93B-48E1-ADA9-17AD5564CC8EQ36767358-80882725-ACFF-46F9-8DAB-6F7089EE2AC9Q36972789-6670068E-87F8-4740-9FF6-3D03D5360BF9Q38180808-3E061835-FA63-4C60-8A30-6467243D16D5Q38408427-ABD1E603-8C4D-4A7E-8EB2-174F41F0D205Q38697736-433D094E-30B8-436E-904E-302A314827DEQ38847475-5C3D04C6-F1D6-4819-B07E-4B1483F84B04Q38944293-DA0039F9-4D76-4A6A-83C4-B8974BCBDE51Q38947280-F1C427EB-E451-4792-AEA3-10CD8B101886Q39186096-AB4400AF-FE7B-4783-BE96-5EDF5593D991Q39512836-05996248-AEB0-4048-860F-703431A989F1Q40343618-001A0B43-15EB-4228-8F13-8ECE3A4132FBQ40855302-948EB54C-6C0C-4B1C-878A-570995F4B5AAQ40933776-73DF95F0-C228-4222-ABCD-13C2C6383B98Q41135859-D577188C-1C42-4E84-9CCE-11B4FE7CFEE3Q42004628-CEB3358A-7C60-4AE6-8AD6-114D57142C81Q42475808-E3D82BD5-2A55-4515-B69E-D28B59F931ADQ42493873-305426E2-39B7-403A-A673-C42F3AD969F8Q42500348-3D585A60-ACAD-43F9-9C7B-23EF03D4DFF0Q42509945-252139FD-BD00-4CDB-84D2-0AE1FA78D27FQ42662364-EF16D402-514F-4CAB-8E2E-7E21E27214DEQ43266903-892BCAAB-8C42-42CB-BC90-A0CBC736EFF4Q44276810-35DCA555-0CCC-4D32-B60C-39F7B26B9E75Q44566943-0788E2AB-470E-40AC-A8E3-9CD5365B51D9Q44834663-C1628D06-8757-4A52-A9B4-DA94C1518AFAQ45969411-90231572-7953-4B8B-8F83-B7E2F7F0FBD3Q46118447-7A439E83-B540-4361-AE3E-8364F037EC36
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clemens O. Hanemann
@ast
Clemens O. Hanemann
@en
Clemens O. Hanemann
@es
Clemens O. Hanemann
@nl
Clemens O. Hanemann
@sl
type
label
Clemens O. Hanemann
@ast
Clemens O. Hanemann
@en
Clemens O. Hanemann
@es
Clemens O. Hanemann
@nl
Clemens O. Hanemann
@sl
prefLabel
Clemens O. Hanemann
@ast
Clemens O. Hanemann
@en
Clemens O. Hanemann
@es
Clemens O. Hanemann
@nl
Clemens O. Hanemann
@sl
P106
P1153
7003471503
P21
P31
P496
0000-0002-1951-1025